#USA #New York #Women's Health #FEMSelect #ARMS Medical

FEMSelect Expands Pelvic Health Platform through Strategic Alliance

FEMSelect, a medical technology firm helmed by women, is set to reshape the pelvic health landscape through a new collaboration with ARMS Medical. This strategic distribution agreement, announced on December 16, 2025, signifies an important step toward expanding the range of pelvic reconstruction solutions available to healthcare providers.

A Collaborative Effort for Women's Health
The partnership leverages ARMS Medical's expertise in biologic grafts and associated surgical instruments for pelvic reconstruction. With a robust product line centered around their standout offerings, including VNEW® precut decellularized dermal allografts, FEMSelect looks to integrate these biologic implants into its already successful commercial framework, particularly enhancing its EnPlace® method for pelvic organ prolapse repair.

Broadening Surgical Options
With a track record of treating over 10,000 patients and collaborating with 200 surgeons nationwide, ARMS Medical brings a wealth of experience and a recognized presence in urogynecology and pelvic reconstruction. The alliance is expected to amplify FEMSelect's reach significantly, providing surgeons with vital options as they navigate surgical methods in this critical area of women's health.

"FEMSelect is committed to enriching the healthcare environment for pelvic health practitioners, ensuring that they have access to a diverse range of biologic solutions," noted Sasha Schrode, Chief Executive Officer of FEMSelect. She emphasized that the integration of VNEW® and ARMS Medical’s broader biologic offerings aligns perfectly with FEMSelect’s innovation goals and enriches the range of solutions available for surgeons.

Growth through Innovation
The partnership with ARMS Medical is part of FEMSelect's broader strategy to enhance its product offerings and establish itself as a leading force in the women's health sector. Recent growth initiatives have included the launch of Elitone, a non-surgical treatment for incontinence, and the company's efforts to expand its international presence, alongside a corporate inversion aimed at positioning FEMSelect for broader strategic expansion.

A Vision for the Future
"Our shared goal is to empower surgeons with exemplary biologic and surgical options that facilitate informed, responsible approaches to pelvic reconstruction," said Robert Greer, Chief Executive Officer of ARMS Medical. With the commercial capabilities of FEMSelect and the adoption of the EnPlace® technique within urogynecology, this collaboration promises to be mutually beneficial as both companies move forward together.

About FEMSelect

FEMSelect is devoted to driving advancements in women's pelvic health, focusing intently on disorders of the pelvic floor. The company’s flagship technology, EnPlace®, is a minimally invasive solution that avoids traditional mesh systems, providing substantial safety and reliability metrics. FEMSelect strives to become a dominant entity in the field through targeted development and exceptional commercial execution across its technology portfolio.

About ARMS Medical

ARMS Medical is a Service-Disabled Veteran-Owned Small Business dedicated to offering biologic grafts and surgical tools for pelvic floor reconstruction. Engaging with surgeons nationwide, the company emphasizes responsible surgical practices that are anatomically informed, thereby delivering vital support for pelvic surgery initiatives.

This partnership signifies a promising advancement in addressing the complexities surrounding women’s health, encapsulating the spirit of innovation and collaboration essential for progress in medical technology.